Mark DürkopCEO and Principal Investigator at Novasign GmbH and Department of Biotechnology at BOKU Vienna
With more than 10 years of experience, Mark is a passionate scientist in the field of biopharmaceutical process development. He worked together with several Top25 Pharma companies in different projects targeting their needs in process development and understanding. Together with his team, he is developing a QbD software for both up and downstream processes. This software utilizes AI applied to process data and first principle models (hybrid models) to quickly predict critical quality attributes (CQAs) from critical process parameters (CPPs). Hereby, bioprocess development and characterization will be accelerated significantly while simultaneously a better process understanding is gathered. From this research project, the company Novasign was founded in 2019 offering this unique software solution.